课题基金 / 基金详情

RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS

RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
雷洛昔芬盐酸盐和安慰剂预防绝经后骨质疏松症
批准号：
6291203
负责人：
C. CONRAD JOHNSTON
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291203
关键词：
chemoprevention clinical research drug screening /evaluation estrogen inhibitor female human subject human therapy evaluation osteoporosis placebos postmenopause skeletal disorder chemotherapy women's health

项目摘要

项目成果

C. CONRAD JOHNSTON的其他基金

相似基金

相关文献

中文摘要
翻译
一项多中心、双盲、安慰剂对照研究，研究了8个研究中心的500多名受试者。 受试者将被随机分配至4个平行治疗组。 这项III期试验的目的是在健康受试者中确定长期雷洛昔芬治疗与安慰剂相比的效果。
英文摘要
A multi-center, double-blind, placebo controlled study studying over 500 subjects at 8 study sites. Subjects will be randomly assigned to 4 parallel therapy groups. The objectives of this phase III trial are to establish the effect of long-term Raloxifene therapy, compared with placebo in healthy subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF SEX STEROIDS IN AGE-RELATED BONE LOSS
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY
海外基金